Migrolyt is a new remedy against migraine, planned to come onto the market after around 2019 as a new product without any competition. Serious cases can already be treated under the framework of a research and development studies! Many migraine patients have already been treated with the prototype, successfully becoming free of migraine. In Germany the costs of business losses through absence on grounds of migraine are estimated at around a billion euro p.a. With Migrolyt the benefits will be substantial. The planned name is not yet protected and so we are using “Migrolyt” as the working name.